<?xml version="1.0" encoding="UTF-8"?>
<document id="DrugDDI.d280" origId="Altretamine"><sentence id="DrugDDI.d280.s0" origId="s0" text="Concurrent administration of HEXALEN and antidepressants of the MAO inhibitor class may cause severe orthostatic hypotension.Cimetidine, an inhibitor of microsomal drug metabolism, increased altretamines half-life and toxicity in a rat model."><entity id="DrugDDI.d280.s0.e0" origId="s0.p1" charOffset="29-36" type="drug" text="HEXALEN"/><entity id="DrugDDI.d280.s0.e1" origId="s0.p3" charOffset="41-56" type="drug" text="antidepressants"/><entity id="DrugDDI.d280.s0.e2" origId="s0.p4" charOffset="64-77" type="drug" text="MAO inhibitor"/><entity id="DrugDDI.d280.s0.e3" origId="s0.p7" charOffset="125-135" type="drug" text="Cimetidine"/><entity id="DrugDDI.d280.s0.e4" origId="s0.p11" charOffset="191-202" type="drug" text="altretamine"/><pair id="DrugDDI.d280.s0.p0" e1="DrugDDI.d280.s0.e0" e2="DrugDDI.d280.s0.e1" interaction="true"/><pair id="DrugDDI.d280.s0.p1" e1="DrugDDI.d280.s0.e0" e2="DrugDDI.d280.s0.e2" interaction="true"/><pair id="DrugDDI.d280.s0.p2" e1="DrugDDI.d280.s0.e0" e2="DrugDDI.d280.s0.e3" interaction="false"/><pair id="DrugDDI.d280.s0.p3" e1="DrugDDI.d280.s0.e0" e2="DrugDDI.d280.s0.e4" interaction="false"/><pair id="DrugDDI.d280.s0.p4" e1="DrugDDI.d280.s0.e1" e2="DrugDDI.d280.s0.e2" interaction="false"/><pair id="DrugDDI.d280.s0.p5" e1="DrugDDI.d280.s0.e1" e2="DrugDDI.d280.s0.e3" interaction="false"/><pair id="DrugDDI.d280.s0.p6" e1="DrugDDI.d280.s0.e1" e2="DrugDDI.d280.s0.e4" interaction="false"/><pair id="DrugDDI.d280.s0.p7" e1="DrugDDI.d280.s0.e2" e2="DrugDDI.d280.s0.e3" interaction="false"/><pair id="DrugDDI.d280.s0.p8" e1="DrugDDI.d280.s0.e2" e2="DrugDDI.d280.s0.e4" interaction="false"/><pair id="DrugDDI.d280.s0.p9" e1="DrugDDI.d280.s0.e3" e2="DrugDDI.d280.s0.e4" interaction="false"/></sentence><sentence id="DrugDDI.d280.s1" origId="s1" text="Data from a randomized trial of HEXALEN and cisplatin plus or minus pyridoxine in ovarian cancer indicated that pyridoxine significantly reduced neurotoxicity;"><entity id="DrugDDI.d280.s1.e0" origId="s1.p19" charOffset="32-39" type="drug" text="HEXALEN"/><entity id="DrugDDI.d280.s1.e1" origId="s1.p21" charOffset="44-53" type="drug" text="cisplatin"/><entity id="DrugDDI.d280.s1.e2" origId="s1.p25" charOffset="68-78" type="drug" text="pyridoxine"/><entity id="DrugDDI.d280.s1.e3" origId="s1.p28" charOffset="112-122" type="drug" text="pyridoxine"/><pair id="DrugDDI.d280.s1.p0" e1="DrugDDI.d280.s1.e0" e2="DrugDDI.d280.s1.e1" interaction="false"/><pair id="DrugDDI.d280.s1.p1" e1="DrugDDI.d280.s1.e0" e2="DrugDDI.d280.s1.e2" interaction="false"/><pair id="DrugDDI.d280.s1.p2" e1="DrugDDI.d280.s1.e0" e2="DrugDDI.d280.s1.e3" interaction="false"/><pair id="DrugDDI.d280.s1.p3" e1="DrugDDI.d280.s1.e1" e2="DrugDDI.d280.s1.e2" interaction="false"/><pair id="DrugDDI.d280.s1.p4" e1="DrugDDI.d280.s1.e1" e2="DrugDDI.d280.s1.e3" interaction="false"/><pair id="DrugDDI.d280.s1.p5" e1="DrugDDI.d280.s1.e2" e2="DrugDDI.d280.s1.e3" interaction="false"/></sentence><sentence id="DrugDDI.d280.s2" origId="s2" text="however, it adversely affected response duration suggesting that pyridoxine should not be administered with HEXALEN and/or cisplatin.1"><entity id="DrugDDI.d280.s2.e0" origId="s2.p33" charOffset="65-75" type="drug" text="pyridoxine"/><entity id="DrugDDI.d280.s2.e1" origId="s2.p38" charOffset="108-115" type="drug" text="HEXALEN"/><entity id="DrugDDI.d280.s2.e2" origId="s2.p40" charOffset="123-132" type="drug" text="cisplatin"/><pair id="DrugDDI.d280.s2.p0" e1="DrugDDI.d280.s2.e0" e2="DrugDDI.d280.s2.e1" interaction="true"/><pair id="DrugDDI.d280.s2.p1" e1="DrugDDI.d280.s2.e0" e2="DrugDDI.d280.s2.e2" interaction="false"/><pair id="DrugDDI.d280.s2.p2" e1="DrugDDI.d280.s2.e1" e2="DrugDDI.d280.s2.e2" interaction="false"/></sentence></document>